(→Jacques VAN HELDEN) |
|||
Line 4: | Line 4: | ||
==Mireille ANSALDI== | ==Mireille ANSALDI== | ||
− | As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use ''Xylella fastidiosa''’s natural phages, but we met some difficulties. We went to see Ms ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview. | + | As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use [[Team:Aix-Marseille/Xylella_fastidiosa|''Xylella fastidiosa'']]’s natural phages, but we met some difficulties. We went to see Ms ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview. |
− | Thanks to her answers, we learned that '' | + | Thanks to her answers, we learned that [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] certainly has some resistance mechanism, such as CRISPR and restriction enzymes. We had doubts about it, now we are fixed. She also told us that we could work on ''Xanthomonas campestris'' instead of [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] since the binding proteins are similar. Indeed, the work on [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] is not allowed in P1 or P2 labs, whereas Xanthomonas is allowed in P2 security labs. So we will use ''X.campestris'' instead, for more safety. |
− | Finally, she also advises us to look about the prophages. By missing information about specific prophages of ''X.fastidiosa'' and the inducible toxicity by these phages, we let this approach aside. That’s why we end up with the [[Team:Aix-Marseille/Bacteriophages|phage-like particles approach]], our final project. | + | Finally, she also advises us to look about the prophages. By missing information about specific prophages of [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] and the inducible toxicity by these phages, we let this approach aside. That’s why we end up with the [[Team:Aix-Marseille/Bacteriophages|phage-like particles approach]], our final project. |
To sum up, we question our phages approach with an expert opinion. Thanks to her, we change our mind about what we wanted to do. Now we are able to combine the phage’s specificity with the toxine’s efficiency. | To sum up, we question our phages approach with an expert opinion. Thanks to her, we change our mind about what we wanted to do. Now we are able to combine the phage’s specificity with the toxine’s efficiency. | ||
Line 14: | Line 14: | ||
==Jacques VAN HELDEN== | ==Jacques VAN HELDEN== | ||
− | We contacted Jacques van Helden to help us find a strong | + | We contacted Jacques van Helden to help us find a strong [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] promoter sequence and the RBS consensus of the anti-shine Dalgarno of RNA polymerase. |
+ | |||
+ | He also sent us a list of questions so that we could reflect on other important points concerning the specificity of the phage, especially questions regarding the specificity of our phage-like particles and the possibility of recombination between phagemid DNA and M13KO7. Finally, he sent us a list of tracks of some other highly expressed genes and a detailed practical approach. | ||
Thank to him, we explore the rate of production of our PLPs, by [[Team:Aix-Marseille/Model|modeling]] and [[Team:Aix-Marseille/M13_test|testing]] the recombination levels and the production rate of PLPs. | Thank to him, we explore the rate of production of our PLPs, by [[Team:Aix-Marseille/Model|modeling]] and [[Team:Aix-Marseille/M13_test|testing]] the recombination levels and the production rate of PLPs. | ||
Line 20: | Line 22: | ||
==Marie-Agnès JACQUES== | ==Marie-Agnès JACQUES== | ||
− | In a second time, as the project was well defined, we confront it with Marie-Agnes Jacques, who is a researcher specialised in [[Team:Aix-Marseille/Xylella_fastidiosa|'' | + | In a second time, as the project was well defined, we confront it with Marie-Agnes Jacques, who is a researcher specialised in [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] for the INRA. With this interview, we wanted to test the relevancy of our [[Team:Aix-Marseille/Project|project]]. Since we weren’t able to meet her directly, this interview was made by email. |
− | According to her, our presentation needed some work to be clearer, and that’s what we did. The second presentation was more specific on what we wanted to do | + | |
+ | Firstly, we explained her our project and asked what she was thinking about it. According to her, our presentation needed some work to be clearer, and that’s what we did. The second presentation was more specific on what we wanted to do and the exactitude of some aspects was reviewed. She also gives rise to the problem of our solution to be a GMO. | ||
− | Thus, we decide to make a | + | Thus, we decide to make a [[Team:Aix-Marseille/Collaborations|collaboration]] with the [[Team:Evry_Paris-Saclay|iGEM Evry Paris-Saclay]] team which made us a review on the [[Team:Aix-Marseille/Legislation|European commission directives]], to know the different step to get an authorization. |
<div class="row-icons white-icons"> | <div class="row-icons white-icons"> |
Revision as of 14:48, 24 October 2017
Experts' Interviews
Mireille ANSALDI
As the project grows, we had more and more questions about our bacteriophage approach. Indeed, we wanted in the first place to use Xylella fastidiosa’s natural phages, but we met some difficulties. We went to see Ms ANSALDI, who directs the “phage cycle and bacteria metabolism” unity research in LCB, CNRS Marseille, France. As an expert in the field, she is an obvious choice to seek advice on the matter. She generously granted us time for an interview.
Thanks to her answers, we learned that X. fastidiosa certainly has some resistance mechanism, such as CRISPR and restriction enzymes. We had doubts about it, now we are fixed. She also told us that we could work on Xanthomonas campestris instead of X. fastidiosa since the binding proteins are similar. Indeed, the work on X. fastidiosa is not allowed in P1 or P2 labs, whereas Xanthomonas is allowed in P2 security labs. So we will use X.campestris instead, for more safety.
Finally, she also advises us to look about the prophages. By missing information about specific prophages of X. fastidiosa and the inducible toxicity by these phages, we let this approach aside. That’s why we end up with the phage-like particles approach, our final project.
To sum up, we question our phages approach with an expert opinion. Thanks to her, we change our mind about what we wanted to do. Now we are able to combine the phage’s specificity with the toxine’s efficiency.
Jacques VAN HELDEN
We contacted Jacques van Helden to help us find a strong X. fastidiosa promoter sequence and the RBS consensus of the anti-shine Dalgarno of RNA polymerase.
He also sent us a list of questions so that we could reflect on other important points concerning the specificity of the phage, especially questions regarding the specificity of our phage-like particles and the possibility of recombination between phagemid DNA and M13KO7. Finally, he sent us a list of tracks of some other highly expressed genes and a detailed practical approach.
Thank to him, we explore the rate of production of our PLPs, by modeling and testing the recombination levels and the production rate of PLPs.
Marie-Agnès JACQUES
In a second time, as the project was well defined, we confront it with Marie-Agnes Jacques, who is a researcher specialised in X. fastidiosa for the INRA. With this interview, we wanted to test the relevancy of our project. Since we weren’t able to meet her directly, this interview was made by email.
Firstly, we explained her our project and asked what she was thinking about it. According to her, our presentation needed some work to be clearer, and that’s what we did. The second presentation was more specific on what we wanted to do and the exactitude of some aspects was reviewed. She also gives rise to the problem of our solution to be a GMO.
Thus, we decide to make a collaboration with the iGEM Evry Paris-Saclay team which made us a review on the European commission directives, to know the different step to get an authorization.